Medico Intercontinental Limited

ICLF

INE858Q01019

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:45:00 2024-05-08 am EDT			5-day change	1st Jan Change
43.51 ^INR	+0.48%		-3.14%	-53.18%

Apr. 25	Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	CI
Apr. 09	Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	CI

Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director

November 14, 2022 at 07:17 am EST

Medico Intercontinental Limited informed that the Board of Directors of the Company at its meeting held November 14, 2022, inter alia, considered and approved: appointment of Mr. Priyank L Sancheti (DIN: 09784354) as an Additional Independent Director of the Company with immediate effect.

Latest news about Medico Intercontinental Limited

Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	Apr. 25	CI
Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	Apr. 09	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Medico Intercontinental Limited Approves Final Equity Dividend for the Financial Year 2022-23	23-06-30	CI
Medico Intercontinental Limited Approves the Regularisation of Priyank Lalitbhai Sancheti as an Independent Director	23-06-30	CI
Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-06	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI
Medico Intercontinental Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or After July 5, 2023	23-05-29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director	22-11-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director	22-09-28	CI
Medico Intercontinental Limited announced that it expects to receive INR 249.787 million in funding	22-08-26	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Medico Intercontinental Limited Announces Resignation Mr. Hiren Ravindrabhai Shah as Independent Director	22-03-30	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-14	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-15	CI
Medico Intercontinental Limited Appoints Hiren Ravindrabhai Shah as Independent Director	20-09-04	CI
Medico Intercontinental Limited Appoints Hiren Ravindrabhai Shah as an Additional Independent Director	20-08-04	CI

Chart Medico Intercontinental Limited

Duration

Period

More charts

Company Profile

Medico Intercontinental Ltd is engaged in the business of trading of pharmaceutical products. It provides platform to all research-based biopharmaceutical companies. Its product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, OROFACT-PASTE(lamy), OROFACT MOUTH ULCER GEL, CALAMED LOTION and others. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICO INTERCONTINENTAL LIMITED	-53.18%	5.19M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.55%	43.57B
OTSUKA HOLDINGS CO., LTD.	+20.70%	22.7B
SANDOZ GROUP AG	+15.74%	14.32B
CIPLA LIMITED	+11.67%	13.42B
ZYDUS LIFESCIENCES LIMITED	+45.18%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-8.84%	6.98B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.33%	5.51B

Generic Pharmaceuticals